Lv3
378 积分 2023-11-10 加入
Sensitive lateral flow assay for bisulfite-free DNA methylation detection based on the restriction endonuclease GlaI and rolling circle amplification
20天前
已完结
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
1个月前
已关闭
Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database
1个月前
已完结
Drug resistance mechanism of anti-angiogenesis therapy in tumor
2个月前
已完结
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2个月前
已完结
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials
5个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
5个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
5个月前
已完结
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
5个月前
已完结
皖公网安备34019202002308
